Palvella Therapeutics, Inc (PVLA) AI Stock Analysis
PVLA AI stock analysis summary
AI ResearchPalvella Therapeutics, Inc. (PVLA) is a clinical-stage biopharmaceutical company focused on treatments for rare genetic skin diseases. The company generated $0 in revenue over the trailing twelve months and reported an EPS of -$4.85. Its balance sheet holds $250.6M in cash and short-term investments with a net cash position of $250.0M.
- Market cap
- $1.73B
- Revenue (TTM)
- $0
- P/E
- —
- 1Y return
- 64.5% S&P 500 16.8%
- Avg. target
- $231.25 92.2% vs last close
Bull case
- All 15 covering analysts assign a Strong Buy rating, with a mean price target of $231.25 implying 92.2% upside.
- The company holds a strong balance sheet with $250.0M in net cash and a current ratio of 21.18 as of June 30, 2026.
- Shares demonstrated momentum with a 1-year return of 64.5%, exceeding the 16.8% return of the S&P 500.
Bear case
- The company generated $0 in revenue over the trailing twelve months and recorded a net loss resulting in EPS of -$4.85.
- Substantial shareholder dilution occurred over recent years, with the 5-year share count expanding by 1490.2% through FY2025.
- Short interest is elevated, with short percent of float standing at 19.8% as of October 16, 2026.
What Palvella Therapeutics does
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for patients with serious and rare genetic skin diseases. Its lead candidate is QTORIN rapamycin, a novel 3.9% anhydrous topical gel currently in a Phase 3 clinical trial for microcystic lymphatic malformations, as well as in a Phase 2 trial for cutaneous venous malformations. The company is also evaluating QTORIN rapamycin for angiokeratomas and other mTOR-driven skin diseases, and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company was founded and remains based in Wayne, Pennsylvania.
Growth and profitability
Over recent periods, Palvella has operated as a clinical-stage biotech without commercial product sales, generating $0 in revenue over the trailing twelve months ended June 30, 2026. In earlier fiscal reporting, revenue stood at $29.1M in FY2018, peaked at $46.3M in FY2019, and settled at $25.9M in FY2022. Net losses were -$26.8M in FY2018, -$25.5M in FY2019, -$37.2M in FY2020, -$45.7M in FY2021, and -$33.3M in FY2022. Operating margin in FY2022 was -167.8%, influenced by research and development expense of $50.2M. Analysts project revenue of $0 for FY2026, followed by $25.6M in FY2027.
Balance sheet and cash flow
As of June 30, 2026, Palvella reported $250.6M in cash and short-term investments against total debt of $535,000, creating net cash of $250.0M. The company exhibits a current ratio of 21.18 and a debt-to-equity ratio of 0.00 on shareholders' equity of $216.9M. Total assets stood at $253.5M. In FY2022, operating cash flow was -$14.8M and free cash flow was -$14.8M. Over a five-year period through FY2025, the company's share count increased 1490.2%.
Valuation and performance
With a market capitalization of $1.73B and an enterprise value of $1.90B, Palvella trades at a price-to-book multiple of 9.9x. The median of its US-listed Healthcare peers carries a price-to-sales ratio of 4.1x, a trailing P/E of 24.6x, and an EV/EBITDA multiple of 12.0x. Over the past year, PVLA shares rose 64.5%, outperforming the S&P 500 return of 16.8%. Over a five-year period, the stock declined 66.7%, while the S&P 500 gained 83.0%.
What analysts expect
Wall Street coverage includes 15 Strong Buy ratings, with zero Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $231.25, representing an upside of 92.2% from the last close of $120.30. Consensus estimates project an EPS of -$6.43 for the fiscal year ending December 31, 2026, and an EPS of -$7.98 for the following fiscal year. The company recorded 0 EPS beats over the last 4 quarters, and its next earnings date is November 10, 2026.
Key risks and what to watch
- The company posted zero EPS beats across the last 4 quarters while continuing clinical R&D spending.
- Net losses are expected to persist, with analysts projecting an EPS of -$6.43 for FY2026 and -$7.98 for FY2027.
- Return on equity over the trailing twelve months was -46.6%, reflecting ongoing operational cash burn.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this PVLA AI stock analysis
This page is an AI-written research summary of Palvella Therapeutics, Inc (PVLA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: PVLA income statement, PVLA balance sheet, PVLA key metrics, PVLA analyst forecast, PVLA chart. See the PVLA stock overview for the latest quote and news.
PVLA AI stock analysis FAQ
What is Palvella Therapeutics' primary drug candidate?
The company's lead candidate is QTORIN rapamycin, a 3.9% anhydrous topical gel in Phase 3 trials for microcystic lymphatic malformations and Phase 2 trials for cutaneous venous malformations.
Does PVLA pay a dividend?
No, Palvella Therapeutics does not currently pay a dividend as it operates as a clinical-stage biopharmaceutical firm.
What is the consensus analyst price target for PVLA?
The mean analyst price target is $231.25, which represents a 92.2% premium over the last closing price of $120.30.
When does Palvella Therapeutics report earnings next?
Palvella's next earnings report is scheduled for November 10, 2026.